PRINCIPLE found antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19
On Jan. 25, 2021, scientists at the University of Oxford reported that after reviewing interim analyses of both…
On Jan. 25, 2021, scientists at the University of Oxford reported that after reviewing interim analyses of both…
On Jan. 25, 2021, Mateon Therapeutics announced that it was launching its mobile app, ARTIHealthTM, for respiratory health…
On Jan. 25, 2021, Emergent BioSolutions and Humanigen announced a contract development and manufacturing (CDMO) services agreement to…
On Jan. 25, 2021, Nirmidas Biotech announced its second FDA Emergency Use Authorization (EUA) for their COVID-19 rapid…
On Jan. 25, 2021, Moderna announced results from in vitro neutralization studies of sera from individuals vaccinated with…
On Jan. 25, 2021, BD (Becton, Dickinson) announced the publication of a peer-reviewed study that showed BD’s antigen…
On Jan. 25, 2021, Oregon Health & Science University (OHSU) announced a new study demonstrated that antibodies generated…
On Jan. 22, 2021, the NIH announced that in large clinical trial conducted worldwide, full dose anti-coagulation (blood…
On Jan. 22, 2021, COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for…
On Jan. 22, 2021, Aurinia Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA)Â had approved LUPKYNISTM…
On Jan. 22, 2021, Humanigen announced an expansion to the Cooperative Research and Development Agreement (CRADA) that the…
On Jan. 22, 2021, Novavax announced that it had finalized an agreement with the Government of Canada to…
On Jan. 22, 2021, Pfizer and BioNTech announced an advance purchase agreement with COVAX for up to 40…
On Jan. 21, 2021, Zoetis announced it had as expanded its line of recombinant vector vaccines with the…
On Jan. 21, 2021, researchers at the NIH announced they had discovered a new genetic disorder characterized by…
On Jan. 21, 2021, the National Institutes of Health announced results of a small but highly controlled study…
On Jan. 21, 2021, the FDA approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for…
On Jan. 21, 2021, the U.S. Department of Defense (DOD) recommended that adults ages 75 and older should…
On Jan. 21, 2021, NIH researchers announced that after people recover from infection with a virus, the immune…
On Jan. 21, 2021, scientists at the Wellcome Sanger Institute announced they had created a highly detailed map…
On Jan. 21, 2021, Eli Lilly announced that bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19…
On Jan. 21, 2021, VBI Vaccines announced that it expected to initiate the first Phase 1/2 clinical study…
On Jan. 21, 2021, Moderna announced that the first participant has been dosed in the Phase 1/2 study…
On Jan. 21, 2021, Janssen Pharmaceutical announced the FDA had approved CABENUVA (consisting of Janssenï¾’s rilpivirine and ViiV…
On Jan. 21, 2021, Penn Medicine reported that patients with inactive cancer and not currently undergoing treatments also…
On Jan. 21, 2021, XBiotech announced that its COVID-19 candidate True Humanï¾™ antibody therapy may also be used…
On Jan. 19, 2021, a new state of the art institute for antimicrobial research iwasa announced at Oxford…
On Jan. 19, 2021, the Northern Arizona University and TGen, an affiliate of City of Hope, announced results…
On Jan. 19, 2021, ImmunityBio reported findings from a follow-up Molecular Dynamics simulation study of the SARS-CoV-2 spike…
On Jan. 19, 2021, ImmunityBio announced it had received authorization from the South Africa Health Products Regulatory Authority…